What is NAION?

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) is a medical condition in which the blood supply to the optic nerve is suddenly disrupted, causing rapid and often irreversible vision loss. It is one of the most common causes of acute optic nerve-related vision loss in people over 50.

The "non-arteritic" distinction is important: unlike arteritic AION (caused by giant cell arteritis — an inflammatory disease), NAION is not caused by arterial inflammation. Instead, it appears to result from vascular insufficiency — a lack of blood flow to a specific portion of the optic nerve head.

Key finding: A July 2024 study by researchers at Harvard Medical School's Mass Eye and Ear found that semaglutide users (Ozempic/Wegovy) had a 4.28x higher risk of NAION compared to patients on other diabetes medications, and a 7.64x higher risk among those taking it for obesity.

NAION Symptoms

NAION typically presents suddenly, often when waking up in the morning. The classic hallmark is painless vision loss in one eye. Common symptoms include:

  • Sudden, painless vision loss in one eye — often described as "waking up blind"
  • Altitudinal visual field defect — losing the upper or lower half of vision in one eye
  • Blurring or dimness across part of the visual field
  • Reduced color vision or contrast sensitivity in the affected eye
  • Swollen optic disc visible to an ophthalmologist during examination
  • No pain (unlike other optic nerve conditions such as optic neuritis)

The second eye is at risk: approximately 15–25% of patients with NAION in one eye eventually develop it in the other eye within 5 years. Bilateral NAION is profoundly disabling.

How is NAION Diagnosed?

NAION is diagnosed by an ophthalmologist or neuro-ophthalmologist through a combination of:

  • Clinical history: Sudden painless vision loss, patient risk factors
  • Visual acuity testing: Snellen chart or equivalent
  • Visual field testing: Humphrey visual field perimetry showing altitudinal or sector defects
  • Fundoscopy / ophthalmoscopy: Visualization of optic disc edema (swelling)
  • Optical Coherence Tomography (OCT): Imaging of the retinal nerve fiber layer
  • Fluorescein angiography: In some cases, to assess blood flow patterns
  • MRI: To rule out other causes (tumors, demyelinating disease)

Is NAION Treatable?

This is the devastating reality for NAION patients: there is currently no FDA-approved treatment that reliably restores lost vision from NAION.

Historically, treatments attempted have included:

  • High-dose corticosteroids — studies have not shown consistent benefit
  • Aspirin — may reduce risk in the fellow eye, not restorative
  • Intravitreal injections (bevacizumab) — studied but not proven effective
  • Low-vision rehabilitation — helps patients adapt but does not restore sight

A small proportion of patients (approximately 40%) experience some spontaneous partial visual recovery in the months following the event, but most do not recover meaningful vision.

Risk Factors for NAION (Traditional)

Before GLP-1 drugs were identified as a factor, established risk factors for NAION included:

  • Type 2 diabetes (the underlying condition many GLP-1 users are treating)
  • Hypertension (high blood pressure)
  • Hyperlipidemia (high cholesterol)
  • Obstructive sleep apnea
  • Small optic disc ("disc at risk" — crowded optic nerve anatomy)
  • Age over 50
  • Male sex
  • Episodes of nocturnal hypotension (blood pressure drops during sleep)
  • Excessive blood loss or anemia

Critically, the Harvard study controlled for diabetes and obesity — the very conditions GLP-1 drugs treat — and still found a dramatically elevated NAION risk in GLP-1 users compared to patients on other medications for the same conditions. This suggests the drug mechanism itself, not the underlying disease, is contributing to the risk.

The GLP-1 Connection: What the Harvard Study Found

The landmark study was published in JAMA Ophthalmology on July 3, 2024. Researchers from Mass Eye and Ear, a Harvard Medical School teaching hospital, analyzed records of 16,827 patients at their institution. Key methodology and findings:

  • Two cohorts studied: Patients with type 2 diabetes and patients with overweight/obesity
  • Comparison: Semaglutide users vs. patients on other medications for the same conditions
  • Diabetes cohort result: 4.28x increased odds of NAION (adjusted OR 4.28; 95% CI, 1.30–16.20)
  • Obesity cohort result: 7.64x increased odds of NAION (adjusted OR 7.64; 95% CI, 2.21–37.50)
  • Study conclusion: "Individuals prescribed semaglutide should be aware of this potential association"
  • Recommendation: NAION should be included as a potential adverse event in GLP-1 drug labels

The researchers noted that the absolute incidence of NAION remains low, but given the massive number of patients taking these drugs (tens of millions globally), the public health impact is significant.

Why Haven't Drug Labels Been Updated?

As of March 2026, Novo Nordisk has not updated its US labels for Ozempic, Wegovy, or Rybelsus to include NAION as a potential adverse event. This forms a core allegation in the litigation: that the company had access to the emerging scientific evidence and failed to act on it.

Drug manufacturers have a legal duty under FDA regulations to provide adequate warnings about known or reasonably knowable risks. Plaintiffs allege that Novo Nordisk's failure to update labels constitutes a failure to warn — one of the most common and powerful theories in pharmaceutical product liability.

The Economic and Personal Impact of NAION

NAION is not just a medical condition — it is a life-altering event. Patients with significant vision loss face:

  • Loss of driving privileges (major impact on independence in most of the US)
  • Inability to perform fine visual tasks (reading, screen use, detailed work)
  • Career impacts — many visual professions become inaccessible
  • Psychological trauma and depression (vision loss has extremely high rates of comorbid depression)
  • Ongoing costs of low-vision aids and rehabilitation
  • Caregiver dependency in severe bilateral cases

These real-world harms — not just the medical diagnosis — are why NAION cases are considered high-value in mass tort litigation.

NAION and Your Legal Claim

If you were diagnosed with NAION after taking a GLP-1 drug, you may have a legal claim based on the manufacturer's failure to warn. MDL 3163 in the Eastern District of Pennsylvania consolidates these cases before Judge Karen Marston.

The key documents you'll need:

  • Ophthalmology records documenting NAION diagnosis
  • Pharmacy records showing GLP-1 prescription and fill dates
  • Visual field testing results and OCT scans
  • Records of any second-eye involvement

Were You Diagnosed with NAION?

If you experienced sudden vision loss after taking Ozempic, Wegovy, Mounjaro, or another GLP-1 drug, use our free eligibility checker to find out if you have a claim.

Check Your Eligibility →